基因多态性对先天性心脏病儿童舒芬太尼药代动力学的影响 by 李碧莲, 王思怡, 白雪, 刘瑶, 魏伟, 管宴萍, 钟国平, 宋兴荣

“…结论在儿童先天性心脏病介入手术中，<italic>ABCG2 </italic>rs2054576，<italic>CYP3A4</italic> rs2246709和<italic>OPRM1</italic> rs2236257，rs4870266的基因多态性可显著地影响SUF的药代动力学变化。…”
Get full text

Regulation of High-Altitude Hypoxia on the Transcription of CYP450 and UGT1A1 Mediated by PXR and CAR by Ya-bin Duan, Ya-bin Duan, Jun-bo Zhu, Jun-bo Zhu, Jian-xin Yang, Gui-qin Liu, Xue Bai, Ning Qu, Xue-jun Wang, Xiang-yang Li

“…Taken together, our results suggest that hypoxia inhibits CYP1A2, CYP2C9, CYP2E1, CYP3A4, and UGT1A1 expression via the PXR and CAR regulatory pathway.…”
Get full text

A Rare Case of Spontaneous Cardiac Tamponade Induced by Concomitant Use of Rivaroxaban and Amiodarone by Oreoluwa Oladiran, Jared Segal, Ifeanyi Nwosu, Salik Nazir

“…Both rivaroxaban and amiodarone are substrates for the CYP3A4 hepatic pathway, and concomitant use can result in increased plasma rivaroxaban levels causing an increased propensity to bleeding. …”
Get full text

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST by D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii

“…The article is devoted to apixaban use in clinical practice: examination before apixaban administration, clinical situation when laboratory control and monitoring are needed, drugs interactions (at the level of CYP3A4, P-gp), management of patients with bleeding because of apixaban therapy (including antidotes application), perioperative management of patients receiving apixaban.…”
Get full text

Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art by S. R. Gilyarevsky

“…Drug interactions for DOACs, depending on concomitant use of drugs that are inhibitors or inducers of the CYP3A4 enzyme or P-glycoprotein enzymes, are determined by most of the drug interactions of DOACs are considered. …”
Get full text

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST by D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii

“…The article is devoted to apixaban use in clinical practice: examination before apixaban administration, clinical situation when laboratory control and monitoring are needed, drugs interactions (at the level of CYP3A4, P-gp), management of patients with bleeding because of apixaban therapy (including antidotes application), perioperative management of patients receiving apixaban.…”
Get full text

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease by Ahai Luvai, Wycliffe Mbagaya, Alistair S. Hall, Julian H. Barth

“…It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. …”
Get full text

The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia by Pascual Bolufer, Maria Collado, Eva Barragán, José Cervera, María-José Calasanz, Dolors Colomer, José Roman-Gómez, Miguel A. Sanz

“…Background and Objectives We examined common polymorphisms in the genes for glutathione S-transferase (GST), cytochrome P450 (CYP), quinone oxoreductase (NQO1), methylene tetrahydrofolate reductase (MTHFR), and thymidylate synthetase (TYMS) and the role of gender associated with the susceptibility to de novo acute leukemia (AL).Design and Methods We conducted a case-control study analyzing the prevalence of the polymorphisms CYP1A1*2A, CYP2E1*5B, CYP3A4*1B, del{GSTT1}, del{GSTM1}, NQO1*2, MTHFR C6777, and TYMS 2R/3R in 443 patients with AL [302 with acute myeloblastic leukemia (AML) and 141 with acute lymphoblastic leukemia (ALL)] and 454 control volunteers, using polymerase chain reaction (PCR)-based methods.Results We found a higher incidence of del{GSTT1} in patients with AML than among controls (25.6% vs. 13.7%, OR=2.2, p…”
Get full text

Resveratrol as an Inhibitor of Pregnane X Receptor (PXR): Another Lesson in PXR Antagonism by Tomas Smutny, Petr Pavek

“…Resveratrol is now being discussed as a novel agent that is capable of attenuating the PXR-inducible expression of the CYP3A4 gene, although the mechanistic explanation has not been determined. …”
Get full text

Cytochrome P450 humanised mice by Gonzalez Frank J

“…Humanised mice expressing CYP2D6 and CYP3A4, two major drug-metabolising P450s, have revealed the feasibility of this approach.…”
Get full text

Acute Colchicine-induced Neuromyopathy in a Patient Treated with Atorvastatin and Clarithromycin by José M. Olmos-Martínez, Helena Molina, Cristina Salas, José M. Olmos, José L. Hernández

“…Drugs interacting with colchicine metabolism through CYP3A4 can accelerate accumulation and toxicity. We describe a case of an interaction between atorvastatin, clarithromycin and colchicine resulting in acute neuromyopathy.…”
Get full text

Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome by Ngow, Harris Abdullah, Nowalid, Wan Khairina Won Mohd

“…The exact mechanism of the drug interaction remains elusive, though induction of hepatic CYP3A4 enzyme complex is a possible mechanism. In a patient treated with rifampicin, the results of dexamethasone suppression tests thus have no diagnostic value and can be very misleading.…”
Get full text

AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes by Ju-Hyun Kim, Soon-Sang Kwon, Tae Yeon Kong, Jae Chul Cheong, Hee Seung Kim, Moon Kyo In, Hye Suk Lee

“…These in vitro results indicate that AM-2201 needs to be examined for potential pharmacokinetic drug interactions in vivo due to its potent inhibition of CYP2C8, CYP2C9, CYP3A4, UGT1A3, and UGT2B7 enzyme activities.…”
Get full text

CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children by Tigist Dires Gebreyesus, Eyasu Makonnen, Nigus Fikrie Telele, Abbie Barry, Rajabu Hussein Mnkugwe, Heran Gerba, Marja-Liisa Dahl, Eleni Aklillu

“…Genotyping for common functional variants of CYP3A4 (*1B), CYP3A5 (*3, *6), CYP2C19 (*2, *3, *17), CYP2C9 (*2, *3), and CYP2J2*7 was performed. …”
Get full text

Effects of <it>CYP2B6 </it>G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults by Kalambaheti Thareerat, Wichukchinda Nuanjun, Manosuthi Weerawat, Likanonsakul Sirirat, Uttayamakul Sumonmal, Nakayama Emi E, Shioda Tatsuo, Khusmith Srisin

“…Polymorphisms of <it>CYP2B6 </it>and <it>CYP3A4 </it>are associated with altered activity of hepatic enzyme in the liver and pharmacokinetics resulting in treatment efficacy. …”
Get full text

Oral laquinimod treatment in multiple sclerosis by O. Fernández

“…Laquinimod is metabolised primarily by the CYP3A4 enzyme in the liver. Phase II studies in RRMS demonstrate a dose-response effect on disease activity, measured by the number of active lesions on brain magnetic resonance imaging, and show favourable tolerability and safety based on clinical and laboratory indicators. …”
Get full text

Inhibitory mechanism of vortioxetine on CYP450 enzymes in human and rat liver microsomes by Yunyun Zhan, Anzhou Wang, Anzhou Wang, Yige Yu, Jie Chen, Xinhao Xu, Jingjing Nie, Jingjing Lin

“…It was noncompetitive inhibition for CYP3A4 and CYP2C8, and its Ki values were 7.26 μM and 6.96 μM, respectively. …”
Get full text

TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs by Hongbo Wang, Fang Chu, Xiao-feng Zhang, Peng Zhang, Li-xin Li, Yun-long Zhuang, Xiao-feng Niu, Xi He, Zhi-jie Li, Ying Bai, Da Mao, Zhen-wen Liu, Da-li Zhang, Bo-an Li

“…Mechanically, overexpression of TPX2 led to enhancement of PXR recruitment to its downstream gene cyp3a4’s promoter region (the PXRE region) or enhancer region (the XREM region). …”
Get full text

Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a random... by Felicitas Stoll, Antje Blank, Gerd Mikus, David Czock, Kathrin I. Foerster, Simon Hermann, Katja Häußler, Amin Muhareb, Simone Hummler, Johanna Weiss, Jürgen Burhenne, Walter E. Haefeli

“…. • Evaluation of HCQ as a potential perpetrator in drug-drug interactions at the level of cytochrome P450 (CYP) 3A4 and CYP2D6 (major drug metabolizing enzymes). …”
Get full text

Is OPRM1 genotype a valuable predictor of VAS in patients undergoing laparoscopic radical resection of colorectal cancer with fentanyl? by Yan Zhou, Lei Cao, Yihui Yang, Yaoyi Gao, Yihao Li, Beili Wang, Baishen Pan, Jian Huang, Wei Guo

“…When adjusting for age, sex, weight, height, surgery duration, COMT Val158Met gene polymorphism, CYP3A4 *1G gene polymorphism, and CYP3A5 *3gene polymorphism, the OR was 19.94 (P = 0.002). …”
Get full text